注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Pieris Pharmaceuticals Inc是一家临床阶段的生物技术公司,致力于发现和开发基于Anticain的药物,以针对经过验证的疾病途径。该公司的临床产品线包括用于治疗哮喘的吸入IL-4Rα拮抗剂Anticin蛋白,免疫肿瘤学(IO),靶向HER2和4-1BB的双特异性,以及靶向PD-L1和4-1BB的IO双特异性靶向PD-L1和4-1BB。其基于铅呼吸安提卡林的候选药物PRS-060 / AZD1402拮抗IL-4R α,从而抑制IL-4和IL-13这两种细胞因子,这两种细胞因子是介导人体内细胞之间信号传导的小蛋白质,已知是炎症级联反应中的介质,可驱动哮喘和其他炎症性疾病的发病机制。其管道中基于前IO抗提菌素的候选药物cinrebafuspα,其设计用于靶向免疫受体4-1BB和肿瘤靶向HER2。Cinrebafusp alfa是HER2靶向抗体与Anticin蛋白的变体的遗传融合。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Stephen S. Yoder | 47 | 2010 | CEO, President & Director |
Bruce Levy | - | - | Member of Clinical & Scientific Advisory Board |
Michael S. Richman | 62 | 2014 | Independent Director |
Peter Barnes | - | - | Member of Clinical & Scientific Advisory Board |
Padmanee Sharma | - | - | Member of Clinical & Scientific Advisory Board |
Vijay Kumar Kuchroo | 68 | - | Member of Clinical & Scientific Advisory Board |
Christopher P. Kiritsy | 58 | 2016 | Independent Director |
Peter A. Kiener | 71 | 2018 | Independent Director |
Ian Adcock | - | - | Member of Clinical & Scientific Advisory Board |
Gary Anderson | - | - | Member of Clinical & Scientific Advisory Board |
Dario A. Vignali | - | - | Member of Clinical & Scientific Advisory Board |
Matthew L. Sherman | 67 | 2018 | Independent Director |
Oliver Eickelberg | - | - | Member of Clinical & Scientific Advisory Board |
James Arthur Geraghty | 68 | 2017 | Independent Chairman |
Maya R. Said | 46 | 2019 | Independent Director |
David Schwartz | - | - | Member of Clinical & Scientific Advisory Board |
E. John Werry | - | - | Member of Clinical & Scientific Advisory Board |
Michael A. Curran | - | - | Member of Clinical & Scientific Advisory Board |
Ann Barbier | 59 | 2018 | Independent Director |
Fan Chung | - | - | Member of Clinical & Scientific Advisory Board |
Sally Wenzel | - | - | Member of Clinical & Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核